沙库巴曲缬沙坦治疗老年慢性心力衰竭病人效果的Meta分析

doi:10.3969/j.issn.1003-9198.2023.10.011

摘要/Abstract

摘要： 目的系统评价沙库巴曲缬沙坦治疗老年慢性心力衰竭(CHF)病人的有效性和安全性。方法采用计算机检索中国期刊全文数据库(CNKI)、维普中文科技期刊全文数据库(VIP)、中国生物医学文献数据库(CBM)、万方医学数据库、PubMed文献,搜集关于沙库巴曲缬沙坦治疗老年CHF疗效的随机对照试验(RCT),并对文献进行筛选和数据提取,采用RevMan 5.3软件进行Meta分析。结果纳入12项RCT研究,共1299例病人。Meta分析结果显示,沙库巴曲缬沙坦治疗老年CHF(试验组)的效果优于单纯基础治疗(对照组)(RR=1.23,95%CI: 1.18～1.30)。同时,治疗后试验组的LVEF(MD=6.16,95%CI:5.66～6.55)、N末端B型利钠肽原(MD=-363.44,95%CI:-397.35～-329.53)、左心室舒张末期内径(MD=-4.58,95%CI:-6.10～-3.06)、6 min步行距离(MD=57.3,95%CI:23.76～90.84)均优于对照组。12篇文献中有8篇对不良反应进行了报道,结果显示,试验组病人的不良反应发生率与对照组相比差异无统计学意义(RR=0.87,95%CI:0.63～1.20)。结论老年CHF病人使用沙库巴曲缬沙坦可显著改善临床疗效及心功能指标,且未增加不良反应发生率。

关键词: 沙库巴曲缬沙坦, 慢性心力衰竭, 老年人, Meta分析

Abstract: Objective To systematically evaluate the efficacy and safety of sacubitril valsartan in the treatment of chronic heart failure(CHF) in the elderly patients. Methods The related literatures were retrievaled in the databases such as Chinese National Knowledge Infrastructure (CNKI), VIP, China Biology Medicine (CBM), Wanfang database and PubMed. Randomized controlled trials(RCTs)about the efficacy of sacubitril valsartan in the treatment of CHF in the elderly patients were collected. The retrieved literatures were screened and the data were extracted. Meta-analysis was performed by using RevMan 5.3 software. Results A total of 1299 patients from 12 RCTs were enrolled. The results showed that the efficacy of sacubitril valsartan in the treatment of the elderly patients with CHF (experiment group) was better than basic treatment alone (control group) (RR =1.23,95%CI: 1.18-1.30). Meanwhile, the left ventricular ejection fraction(MD=6.16,95%CI:5.66-6.55), N-terminal pro B-type natriuretic peptide(MD=-363.44,95%CI:-397.35--329.53), left ventricular end-diastolic dimension (MD=-4.58,95%CI:-6.10--3.06)and 6-minute walk distance(MD=57.3,95%CI:23.76-90.84) in experiment group were more significantly improved than those in the control group. The incidence of adverse reactions was reported in 8 out of 12 articles. The results showed that there was no significant difference in the incidence rate of adverse reactions between the two groups(RR=0.87,95%CI:0.63-1.20). Conclusions The treatment of sacubitril valsartan in the elderly patients with CHF can significantly improve the clinical efficacy and cardiac function, while the incidence of adverse reactions is not increased.

Key words: sacubitril valsartan, chronic heart failure, aged, Meta-analysis

中图分类号:

R 541.61

李善淑, 吕逸宁, 宫慧敏, 张改改. 沙库巴曲缬沙坦治疗老年慢性心力衰竭病人效果的Meta分析[J]. 实用老年医学, 2023, 37(10): 1023-1026.

LI Shan-shu, LYU Yi-ning, GONG Hui-min, ZHANG Gai-gai. Meta-analysis of sacubitril valsartan in the treatment of elderly patients with chronic heart failure[J]. Practical Geriatrics, 2023, 37(10): 1023-1026.

参考文献

[1] MOSTERD A, HOES A W. Clinical epidemiology of heart failure[J]. Heart, 2007, 93(9): 1137-1146.
[2] WANG H, CHAI K, DU M, et al. Prevalence and incidence of heart failure among urban patients in China: a national population-based analysis[J]. Circ Heart Fail, 2021, 14(10): 1127-1135.
[3] PONIKOWSKI P, VOORS A A, ANKER S D, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur Heart J, 2016, 37(27): 2129-2200.
[4] 中华医学会心血管病学分会心力衰竭学组与中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10): 760-789.
[5] GAO Y,XING C,HAO W,et al. The impact of Sacrubitril/Valsartan on clinical treatment and hs-cTnT and NT-ProBNP serum levels and the left ventricular function in patients with chronic heart failure[J]. Inter Heart J, 2020, 61(1): 1-6.
[6] 刘锦涛. 沙库巴曲缬沙坦钠片治疗老年重症心力衰竭的效果分析[J]. 当代医学,2021,27(34):116-118.
[7] 孟攀升,马宏喜.长期服用沙库巴曲缬沙坦钠对老年慢性心衰患者心功能指标,血清cTnI和cTnT水平的影响[J]. 临床医学研究与实践, 2019, 4(30): 59-61.
[8] 常雨.沙库巴曲缬沙坦钠片治疗老年慢性心功能不全的临床效果观察[J]. 中国现代药物应用, 2021, 15(17): 160-163.
[9] 庞翀,郑菊,王彩虹,等. 沙库巴曲缬沙坦治疗老年射血分数降低型心力衰竭患者的临床疗效[J]. 中国临床药理学杂志, 2021, 37(20): 2731-2733,2737.
[10] 张勇, 沙库巴曲缬沙坦治疗老年心力衰竭临床疗效[J]. 天津药学, 2021, 33(1): 26-27.
[11] 戴玮鑫,高鹏,王文海,等. 沙库巴曲缬沙坦治疗老年慢性心衰急性加重患者的临床效果及对NT-proBNP,hs-CRP,心功能,生活质量的影响分析[J]. 中华养生保健, 2021, 39(14): 140-142.
[12] 杨昌林, 沙库巴曲缬沙坦钠片治疗高龄慢性心力衰竭效果观察[J]. 人民军医, 2019, 62(9): 847-849,855.
[13] 秦少强,张占帅,石金铮,等. 沙库巴曲缬沙坦治疗老年慢性心功能不全的疗效及机制研究[J]. 实用老年医学, 2021, 35(8): 837-839,848.
[14] 简春燕,吴一帆,陈旭松,等. 探讨沙库巴曲缬沙坦治疗高龄射血分数降低心力衰竭患者的临床疗效[J]. 中国实用医药, 2020, 15(14): 118-120.
[15] 陈兆彦,孙强. 沙库巴曲缬沙坦对顽固性心力衰竭患者康复治疗及左心室射血分数的影响[J]. 中华老年心脑血管病杂志, 2021, 23(4): 379-382.
[16] 陈莉,逯伟达,吴媛媛,等. 沙库巴曲缬沙坦对射血分数降低的心力衰竭Ⅳ级患者生化指标和左心室结构的干预作用[J]. 中华老年医学杂志, 2019, 38(5): 525-528.